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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016currently under development. We thus studied the therapeutic
potential of interference with ROR t activation in biTregs using the
model of pristane induced chronic systemic lupus erythematosus
(SLE).
Methods: Foxp3Cre x RORCﬂ/ﬂ mice with selective deﬁciency of
ROR t in biTregs were generated (biTregROR-). SLE was induced
by i.p. injection of pristane oil. Systemic auto-immunity, renal
immune responses and tissue injury were studied between 2 and
8 months after disease induction.
Results: Time course analyses showed increasing inﬁltration of
biTregs into kidneys of pristane injected mice with a maximum at
around 5 months. In order to study the functional role of ROR t in
biTregs, the course of SLE was analyzed in biTregROR- mice.
Assessment of renal histology at 8 months showed severe prolif-
erative glomerulonephritis in pristane injected wild type mice.
Histological injury and glomerular cell proliferation in the biTre-
gROR- group, in contrast, was signiﬁcantly ameliorated. In line,
renal inﬂammatory leukocyte inﬁltration, blood urea nitrogen
levels and albuminuria were also reduced by knockout of ROR t in
biTregs. As one possible explanation for the improved outcome, we
found that biTregs from wild type mice produced pro-inﬂammatory
IL-17 at all observed time points, while biTregs from biTregROR-
mice did not. Furthermore, systemic and organ speciﬁc immune
responses were strikingly skewed towards protective Th2 immu-
nity in biTregROR- mice. Next, effects of biTreg expressed ROR t
on development of humoral auto-immunity were studied. Analyses,
however, showed unaltered serum anti-U1-RNP auto-antibody
levels of all isotypes. Likewise, renal IgG and complement C3
deposition remained unchanged. This indicates that ROR t activa-
tion in biTregs directs renal injury by cellular effectors but does
not play a major role for generation of humoral auto-immunity.
Conclusions: In summary, our data thus provide ﬁrst evidence for
presence and functional importance of biTregs in SLE. Importantly,
biTreg expressed ROR t was identiﬁed as factor promoting devel-
opment of renal injury via induction of IL-17 secretion and sup-
pression of Th2 immunity. Our data therefore favor ROR t directed
interventions as innovative new therapeutic option for lupus
nephritis.
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Introduction: Adoptive transfer of regulatory T cells (Tregs) rep-
resents a promising strategy to modulate autoimmune diseases
including renal diseases, as well as bone marrow and organ trans-
plantation. Studies performed in mice and humans have shown the
feasibility of generating Treg ex vivo from naive T cells (nT) in the
presence of IL-2 / TGF , all-trans retinoic acid (atRA) and rapamycin
(RAPA). This study reports the expansion, differential expression
of homing receptors; methylation of the conserved non-coding
sequence 2 (CNCS2) of foxp3, and function of polyclonal human
Treg induced from nT in short-term cultures.
Methods: nT were isolated from healthy volunteers by negative
selection, polyclonally stimulated with anti-CD3 plus anti-CD28S12antibodies and cultured in the presence of IL-2 and TGF for 5 days.
RAPA and/or atRA were added at different concentrations. The
induced Tregs were characterized by ﬂow cytometry and sup-
pression assays in vitro, methylation of the CNCS2 was evaluated
by bisulphite conversion and pyro-sequencing.
Results: Results show that atRA improves while Rapa reduces the
generation of Treg in this short-term setting. atRA enhanced the
expression of 7, while the expression of CXCR4 is increased by
RAPA. Functional assessment showed that Treg generated in the
presence of RAPA had the highest suppressor effect. Methylation
assays showed that atRA and RAPA did not lower the high
methylation of the induced Treg, however polyclonal re-stimula-
tion in the presence of atRA and RAPA was related to diminished
methylation of the CNCS2.
Conclusions: These results show that the presence of atRA and
RAPA contributes to the generation and function of induced Treg,
providing each a differential expression of homing receptors.
Repeated polyclonal stimulation in the presence of atRA and RAPA
may contribute to decrease the methylation of the critical CNCS2.
These results open the possibility of modulating the phenotype and
function of Treg generated ex vivo, thus manufacturing Treg with
diverse characteristics depending on the context and clinical
purpose.
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Introduction: Approximately 5% of children with MCD and even
more number of MCD in adults are steroid resistant. Of those pa-
tients who are found to have FSGS, about 15% will respond to
conventional oral steroid therapy, remaining 85% of patients are
steroid resistant and are at substantial risk to progress to ESRD.
Thus, present study was undertaken to know underlying different
etiologies with special emphasis to calcineurin inhibitors as a
treatment options for frequent relapsing and steroid resistant
nephrotic syndrome in both children and adults.
Methods: The present study was an observational analysis of 30
patients with frequently relapsing or steroid resistant nephrotic
syndrome treated with calcineurin inhibitors in addition to low
dose steroid therapy presenting to the IKDRC-ITS, during the
period from September 2012 to March 2015. Inclusion criteria:
FRNS & SRNS were deﬁned by KDIGO guidelines. Only patients
undergone renal biopsy to deﬁne morphology were included. FRNS
or SRNS patients treated with calcineurin inhibitors (Cyclosporine
or Tacrolimus) at least for 6 months to deﬁne response were
included. Exclusion criteria: 1. Children < 1 year of age (to exclude
congenital nephrotic syndrome). 2. Patients with systemic disease
like lupus, diabetes and other causes of secondary nephrotic syn-
drome were excluded. As per recommendations of KDIGO, patients
with FRNS & SRNS were treated with cyclosporine or tacrolimus
for a minimum of 6 month period.
Results: Overall FSGS was the most common etiology in 13 (44%)
patients followed by IgM nephropathy in 8 (26%) patients, MePGN
in 5 (17%) and MCD in 4 (13%) patients. After 3 months of
treatment with CNI in majority of patients, proteinuria reduced to
subnephrotic range and Sr. albumin increased to >2.5 gm/dl. Renal
function remained stable during CNI treatment. OverallKidney International Reports (2016) 1, S1–S22
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016cyclosporine was successful in 75% of patients in treating frequent
relapses. Mean time to achieve remission was 3.2 months. Overall
Tacrolimus was successful in 77% of patients in treating frequent
relapses. Mean time to achieve remission was 2.1 months. Out of 15
patients with steroid resistant nephrotic syndrome, 3 patients
treated with cyclosporine, 1 achieved partial remission and still
continued on CSA where as 2 patients did not respond. Time to
achieve remission was 5 months. 2 patients resistant to cyclosporine
and 12 steroid resistant patients were treated with tacrolimus (total
14 patients). 11 of 14 (79%) patients achieved complete remission
and 2(14%) achieved partial remission. Mean time to achieve
remission was 2.5 months. In SRNS patients, tacrolimus was more
effective than cyclosporine and was also effective in 1 pt resistant
to CSA.
Conclusions: In frequent relapsing nephrotic syndrome patients,
both cyclosporine and tacrolimus has comparable efﬁcacy and no
signiﬁcant difference. Overall success rate (CR, PR and infrequent
relapses) was 75% and 77% respectively. In steroid resistant
nephrotic syndrome patients, tacrolimus was more effective than
cyclosporine and also effective in CSA resistant patients. Combined
remission rate (CR & PR) of 93% with tacrolimus as compare to only
33% with cyclosporine was achieved in SRNS. Late steroid resis-
tance is associated with better response to CNI therapy as compared
to primary CNI resistance.
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Introduction: Current guidelines suggest treatment with cortico-
steroids (CS) in IgA nephropathy (IgAN) with persistent proteinuria
>1 g/day despite 3–6 months of supportive care and eGFR
>50 ml/min/1.73m2. Whether the beneﬁts of this treatment extend
to patients with an eGFR<50 ml/min/1.73m2 is unclear. We
retrospectively studied the effect of steroids on disease progression
and proteinuria in IgA N patients with eGFR < 50ml/min/1.73m2
compared to those with >50ml/min/1.73m2.
Methods: A cohort of biopsy proven primary IgA N diagnosed
between March 2010 and February 2015 who received oral corti-
costeroids and followed-up for a minimum of six months were
included. They were categorized into two groups as per eGFR.
(Group 1 – eGFR>50 ml/min/1.73m2, Group 2 – eGFR < 50ml/min/
1.73m2). Baseline characteristics were compared between the
groups. The eGFR and urine protein creatinine ratio (UPCR) were
followed up at entry time, 6 months, 12 months and at the end of
follow-up. Outcomes studied were change in eGFR, proteinuria and
progression to end stage renal disease (ESRD). Statistical analysis
was done using SPSS version 16.
Results: Out of 44 patients, 23(52%) had eGFR< 50 ml/min/1.73m2
(Group1) and 21(48%) had eGFR >50ml/min/1.73m2 (Group 2). The
baseline clinical, histopathological, and treatment characteristics of
both the groups are shown in table 1. At the end of follow-up,Kidney International Reports (2016) 1, S1–S22similar reduction of proteinuria (UPCR) (p-0.62) was seen in both
the groups. But there was signiﬁcant difference in change in me-
dian eGFR/month (p-0.004) (Table 2). Patients in Group 2 had a
median fall in eGFR of -0.46 ml/min/1.73m2 / month, whereas
Group 1 had an increase in median eGFR by +0.38ml/min/1.73m2/
month (Table 2). One in each group has reached CKD stage
5(p-0.73). Limitations in our study were retrospective in nature,
small cohort and short duration of follow-up.
Table 2. Outcomes at the end of follow-up between groups
Group 1(N[23) (%) Group 2-(N-21)(%)Characteristic
(eGFR < 50
ml/min/1.73m2)
(eGFR > 50
ml/min/1.73m2)
‘p’
valueInitial eGFR# 25.13(19.33,39.51) 82.7(76,115.85)eGFR at end of follow-
up#20.94(9.36,37.12) 94.43(77.48,129.91)Change in eGFR/
month#-0.46(-0.1,-1.08) +0.38(+1.06,0.00) 0.004Initial UPCR# 2.6(1.8,3.3) 2(1.7,3.1)UPCR at the end of
follow-up#1.0(0.6,2.0) 1.0(0.6,2.0)Change in UPCR# 1.4(0.3,2.0) 1.5(0.55,2.75) 0.61Patients reaching ESRD 1(4.3) 1(4.7) 0.73#- Median with interquartile range, *- Mean with standard deviation, estimated
glomerular ﬁltration rate (eGFR), Urine protein-to- creatinine ratio(UPCR)
Conclusions: Addition of corticosteroids to conservative treatment
in IgA N patients with initial eGFR<50 ml/min/1.73m2 seems to
reduce proteinuria but not beneﬁcial in preventing progression of
disease as compared to patients with higher eGFR (>50ml/ min/
1.73m2). However we need large prospective randomized control
trials with long term follow-up to conﬁrm role of steroids in this
subset of IgA N.
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